Preferred Label : Autologous Anti-EGFR/Anti-IL13Ralpha2 CAR T-cells;
NCIt synonyms : Autologous Anti-EGFR/IL13Ra2 CAR-T Cells; Autologous Anti-EGFR/IL13Ra2 CAR T Cells; CART-EGFR-IL13Ra2 Cells; Autologous Anti-EGFR/Anti-IL13Ra2 CAR T-cells;
NCIt definition : A preparation of autologous T-lymphocytes engineered to co-express two chimeric antigen
receptors (CARs) specific for epidermal growth factor receptor (EGFR) epitope 806
and interleukin-13 receptor alpha 2 (IL13Ra2), with potential immunostimulating and
antineoplastic activities. After isolation, transduction, expansion and reintroduction
into the patient, the autologous anti-EGFR/anti-IL13Ra2 CAR T-cells are directed to,
bind to, and induce selective toxicity in EGFR deletion mutation variant III (EGFRvIII)-expressing
and IL13Ra2-expressing tumor cells. EGFRvIII, an in-frame deletion of exons 2-7 in
the EGFR gene, is overexpressed by a variety of cancer cell types but absent in normal,
healthy cells. It plays a key role in tumor cell proliferation, tumor angiogenesis
and resistance to both radio- and chemotherapy. IL13Ra2, a cancer-associated receptor,
is overexpressed by a variety of tumor cell types including glioblastoma multiforme
(GBM); it is associated with increased invasiveness of tumor cells. The binding of
IL13Ra2 to EGFRvIII upregulates the tyrosine kinase activity of EGFRvIII and promotes
tumor cell proliferation.;
NCI Metathesaurus CUI : CL1773927;
Origin ID : C185590;
UMLS CUI : C5669986;
Semantic type(s)
- Cell [UMLS semantic type]
- chemical_or_drug_affects_cell_type_or_tissue
- chemical_or_drug_has_mechanism_of_action
- chemical_or_drug_has_physiologic_effect
- concept_is_in_subset
- has_target
